利伐沙班与免疫球蛋白疗法治疗类脂质渐进性坏死性血管病的疗效比较：一项系统评价
Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
作者信息
Ramphall Shivana, Rijal Swarnima, Prakash Vishakh, Ekladios Heba, Mulayamkuzhiyil Saju Jiya, Mandal Naishal, Kham Nang I, Shahid Rabia, Naik Shaili S, Venugopal Sathish
机构信息
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
出版信息
Cureus. 2022 Aug 27;14(8):e28485. doi: 10.7759/cureus.28485. eCollection 2022 Aug.
Livedoid vasculopathy (LV) is an uncommon chronic coagulation disorder whose underlying etiology is not yet fully understood. It predominantly affects females, especially those in late adolescence. There is currently limited research on treatment options for those with this diagnosis. The present systematic review aims to compare the efficacy of rivaroxaban and intravenous immunoglobulin (IVIG) therapy in the treatment of livedoid vasculopathy. A detailed search was conducted from April 20, 2022, to May 1, 2022, using four databases: Elsevier, Medline Complete, Medline Ovid, and PubMed. Out of these, 20 relevant articles were used, and the data was extracted and analyzed. Both rivaroxaban and IVIG were shown to be effective treatment options with similar treatment response times. However, future large-scale clinical trials are needed to determine an established treatment regimen for these patients.
萎缩性血管病（LV）是一种罕见的慢性凝血障碍疾病，其潜在病因尚未完全明确。它主要影响女性，尤其是青春期晚期的女性。目前针对该诊断患者的治疗选择研究有限。本系统评价旨在比较利伐沙班和静脉注射免疫球蛋白（IVIG）疗法治疗萎缩性血管病的疗效。于2022年4月20日至2022年5月1日使用四个数据库进行了详细检索：爱思唯尔、医学全库、医学Ovid数据库和PubMed。其中，使用了20篇相关文章，并对数据进行了提取和分析。利伐沙班和IVIG均显示为有效的治疗选择，治疗反应时间相似。然而，未来需要进行大规模临床试验以确定针对这些患者的既定治疗方案。
Zotero 插件